Left Atrial Appendage Closure Devices Market - By Product, By Procedure, By End Use – Global Forecast, 2024 – 2032

Left Atrial Appendage Closure Devices Market Size

The global left atrial appendage closure devices market size was valued at USD 1.8 billion in 2023 and is expected to exhibit growth at a CAGR of 19.2% from 2024 – 2032 period. The growing adoption rate of advanced technologies, and the government policies, among others, are some of the imperative factors that support industry growth.
 

The implantations of left atrial appendage closure techniques are essential for stroke prevention in patients with atrial fibrillation. These techniques can also be used in patients undergoing heart surgery who have atrial fibrillation. A recent study of more than 10,000 records of patients who underwent cardiac surgery indicated that 37% of patient’s had left atrial appendage closure in the U.S. Furthermore, the Watchman device is one that has been investigated extensively and is safe to use after more than 300,000 procedures. Therefore, the procedural success rate is phenomenal. In this manner, it is expected that the market will be propelled due to the enormous potential in left atrial appendage closure devices.
 

Moreover, improvements in the technology of the devices are allowing more people to embrace these procedures globally because of the increased safety and effectiveness of the procedures. There is also increased supply due to a rise in health awareness as well as general adoption of the clinical guidelines of the procedures. There is also an increase in expenditure in the healthcare sector, affordability of modern cardiovascular devices, and more LAA procedures being reimbursed in various countries which are beneficial for market growth globally.
 

Left atrial appendage (LAA) closure devices, or left atrial appendage occlusion devices, aim to mitigate the risk of LAA-originated blood clots entering the systemic circulation and provoking a stroke in patients with a non-valvular atrial fibrillation (AF) condition.
 

Left Atrial Appendage Closure Devices Market Trends

The industry of LAA blood clot closure devices is growing largely owing to technological improvements as the designs introduced enhance safety, efficacy, and patient results.
 

• Among the notable innovations is the Medtronic Penditure LAAC device that features advanced sealing technology and optimized deployment mechanisms. This advanced generation device shortens procedure times while enhancing the closure of left atrial appendages, aiming with fewer complications and gaps in patient safety. This has fueled the LAA closure device market.
   
• Another key innovation is the Boston Scientific Watchman FLX Pro, an upgrade to the commonly shared widely used Watchman FLX device. The improvements incorporated into the Watchman FLX Pro design include frame redesign and enhancement of the anchoring system.
   
• These modifications, combined with the above features, increase overall control during the procedure and secure better closure of the left atrial appendage, therefore minimizing the risk of device-related complications such as leaks or incomplete closure that can cause a stroke.
   

Left Atrial Appendage Closure Devices Market Analysis

Based on product, the market is classified into endocardial LAA devices and epicardial LAA devices. The endocardial LAA devices segment generated the highest revenue of USD 1.6 billion in 2023.
 

• The overall market bloom is attributed to the increased awareness and enhancement in the treatment using endocardial LAA devices which mitigate the possibility of thromboembolic from the Left Atrial Appendage entering the systemic circulation. For instance, as captured by a research publication, the endocardial Watchman device engineered and commercially marketed by Boston Scientific Corporation has an intraoperative implantability success rate of over 98%.
   
• Moreover, the use of endocardial LAA devices in uncontrolled atrial fibrillation patients has been shown to carry a lower overall risk of thromboembolic events when associated complications are appropriately managed. In addition, the use of endocardial LAA closure devices is regarded as one of the safe alternatives in hybrid atrial fibrillation ablation settings.
   

Based on procedure, the left atrial appendage closure devices market is classified into percutaneous and surgical. The percutaneous segment accounted for the majority segmental share in 2023 and was valued at USD 1.7 billion in 2023.
 

• The percutaneous method of LAA closure is a novel approach that is advantageous over anticoagulation therapy in patients with atrial fibrillation who are at a greater risk of having a cerebrovascular accident. This has triggered market players to focus on making self-expanding devices for LAA closure which can be pneumatically deployed.
   
• The technique of percutaneous minimally invasive surgery, known as entry through small incisions that only form scar tissue, along with the hide of external products surgery, has gained much popularity recently for the treatment of certain conditions.
   
• These surgical solutions have emerged as a promising option in patients who are at an elevated risk of strokes in the past few years and especially in those who are not suitable for oral anticoagulants. For instance, the small percutaneous device called the Watchman, approved by the U.S. FDA, is used to block the left atrial appendage opening to stop the formation of blood clots that can be detrimental to patients.
   

Based on end use, the left atrial appendage closure devices market is segmented into hospitals, ambulatory surgical centers, and other end-users. The hospitals segment dominated the market in 2023 and is anticipated to reach USD 6 billion by the end of the forecast period.
 

• The expansion is primarily attributed to the increased adoption of advanced LAA closure devices in surgery, which is expected to enhance the patient's hospital selection. The exponential rise in admissions with target disorders due to sedentary lifestyle, increased disease screening campaigns in combination with the availability of well-trained health professionals are some of the things driving the hospital segment growth.
   
• In addition, the growth of the segment is expected to be further aided due to the high incidence of atrial fibrillation in developing countries with developed healthcare systems.
   
• Moreover, it is projected that the increasing rates of cardiac and renal illnesses associated with fibrillation will increase the rates of diagnosis and treatment in clinics even further, thereby contributing to market growth.
   

North America left atrial appendage closure devices market generated USD 1.3 billion in revenue in 2023 and is projected to grow at a CAGR of 17.6% from 2024 to 2032.
 

• Some of the factors attributed to this case are the presence of more companies, an increase in demand for the products and the increase in the number of people suffering from atrial fibrillation.
   
• Furthermore, industry players like Boston Scientific Corporation and Abbott laboratories are expanding the industry through more investment in research and marketing of new products.
   
• In addition, the increasing number of confined cases of atrial fibrillation and increased patient visits in hospitals strengthen the need for left appendage closure devices. The CDC estimated that 12.1 million cases of people suffering from fibrillation in the U.S. in the next decade. Therefore, there will be greater demand for the left atrial appendage closure devices resulting in an increase in market growth.
   

The U.S. left atrial appendage closure devices market reached USD 1.2 billion in revenue in 2023 and is expected to experience substantial growth from 2024 to 2032.
 

• Supporting policies in respect to reimbursements in the U.S. aid the growth of the device. The Centers for Medicare and Medicaid Services (CMS) has updated its reimbursement policies regarding coverage of LAAC devices, boosting the reimbursement ratios for the WATCHMAN FLX device manufactured by Boston Scientific by 78% between 2015 and 2021. The weighted average reimbursement for LAAC procedures (DRG 273-274) also increased in 2022.
   
• Moreover, with the recent changes in hospital insurance policy and favorable reimbursement policies, there is wider coverage for LAAC devices among hospitals and healthcare providers, facilitating greater reach and access. The country has also had the advantage of wide commercial payer coverage.
   

Germany left atrial appendage closure devices market is expected to grow significantly in the coming years.
 

• Coverage of LAAC procedures in the German health system is comprehensive so that it stimulates the use of the devices by hospitals and the increase in the number of such procedures done. This is expected to persist as more countries in Europe enhance their reimbursement policies.
   
• The increase in the target population and the growing trend towards the use of LAAC devices as a main strategy for the prevention of stroke are propelling the market. This trend is aided by the increasing clinical data validating LAAC's effectiveness in the country.
   

Japan holds a leading position in the Asia Pacific left atrial appendage closure devices market.
 

• The need to raise awareness regarding the benefits of the LAAC procedure among healthcare practitioners and patients is one of the factors that is propelling the overall product sales. Workshops as well as professional education programs are increasing awareness of LAAC advantages, with the result that patients make more educated choices.
   
• The increasing incidence of atrial fibrillation (AF) is one of the key factors fueling the growth rate of the market. As reported by the World Health Organization, Japan is one of the Asian countries where an estimated two-fold increase of AF cases is expected by the year 2030.
   

Left Atrial Appendage Closure Devices Market Share

The global market is witnessing significant growth due to the presence of key participating global players. The market is consolidated in nature with leading companies, smaller regional competition, and new entrants into the industry. Dominant companies like Boston Scientific Corporation, Abbott Laboratories, and the like have a vast array of left atrial appendage closure devices, technological advancement, and have a broad global market.
 

Left Atrial Appendage Closure Devices Market Companies

Prominent players operating in the left atrial appendage closure devices industry include:

• Abbott Laboratories
• AtriCure
• Boston Scientific Corporation
• Lepu Medical Technology
• LifeTech Scientific
• MicroPort Scientific Corporation
• Nanjing YDB Technology
• Shanghai Push Medical Device Technology
   

USPs for the top market players:

• Strong market presence with broad coverage for advanced devices.
   
• Comprehensive product portfolio designed for streamlined procedure with an advanced delivery system
   
• Strong distribution network globally
   

Left Atrial Appendage Closure Devices Industry News:

• In November 2023, Medtronic plc announced the launch of its Penditure left atrial appendage occlusion system in the U.S. The launch of Medtronic's Penditure LAA exclusion system in the U.S. benefited the company by expanding its product offerings in the cardiovascular market, specifically in left atrial appendage management.
   
• In September 2023, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) device. The approval reinforces the company's position as a leader in the LAAC market, providing a competitive edge over other manufacturers.
   

The left atrial appendage closure devices market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million and volume (Units) from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Endocardial LAA devices
• Epicardial LAA devices

Market, By Procedure

• Percutaneous
• Surgical

Market, By End Use

• Hospitals
• Ambulatory surgical centers
• Other end users

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE